BTIG analyst Ryan Zimmerman has maintained their bullish stance on SYK stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ryan Zimmerman has given his Buy rating due to a combination of factors that highlight Stryker’s strong performance and growth potential. The company reported impressive results for the second quarter of 2025, with revenue exceeding expectations and a solid year-over-year growth rate. This performance was achieved despite some challenges, such as supply chain issues in the medical segment and softness in specific areas like Inari. Stryker’s management has also raised its guidance for fiscal year 2025, indicating confidence in continued organic growth and improved earnings per share.
Furthermore, Stryker’s diversified portfolio and its ability to maintain strong operating margins amidst various headwinds underscore its robust business model. The company is seen as a leader in the MedTech industry, with healthy trends in procedural and capital equipment demand. Although the stock experienced a negative reaction post-results due to its high valuation compared to peers, Zimmerman views Stryker as a valuable long-term investment. The premium valuation is justified by Stryker’s consistent growth profile and strategic advancements, such as the successful expansion of its Mako product line.
Zimmerman covers the Healthcare sector, focusing on stocks such as Globus Medical, Stryker, and Zimmer Biomet Holdings. According to TipRanks, Zimmerman has an average return of -2.0% and a 41.34% success rate on recommended stocks.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $435.00 price target.